Preliminary Results of Public Joint Shareholders Company (Final Result Brief for the year ended 31 December 2025)

First - General Information:

Name of the company: Gulf Pharmaceutical Industries PSC (Julphar)

Date Establishment: 1980

Paid up capital: 1,155,227,811

Subscribed capital: 1,155,227,811

Authorized capital: 1,155,227,811

Chairman of the Board: Sheikh Saqer Bin Humaid Al Qassimi

Chief Executive Officer: Basel Nimer Ali Ziyadeh

Name of the external auditor: M/s KPMG Lower Gulf Limited

Mailing address: P.O. Box 997

Tel: +971 7 246 1461

Fax: +971 7246 2462

E – mail: info@julphar.net

Julphar
POBox 997 Ras Al Khaimah
United Arab Emirates

جلفار
صندوق بريد 997 رأس الخيمة
الإمارات العربية المتحدة

T +971 7 246 1461
F +971 7 246 2462
E info@julphar.net

الخليج للصناعات الدوائية
Gulf Pharmaceutical Industries

Second - Preliminary Results (000 AED) :

	2025	2024
Total Assets	**1,818,900**	2,454,600
Shareholders' Equity	**985,800**	818,200
Revenues from continuing operations	**1,059,700**	992,200
Net Operating Profit from continuing operations	**56,200**	46,400
Net profit/(loss) for the year (excluding capital gains)	**56,600**	-2,600
Net profit for the year	**175,300**	35,000
EBITDA from continuing operations	**101,900**	88,600
Earnings per share (fills per share)	**0.15**	-0.01

Summary of the company's performance for the last fiscal year.

The Company's revenues reached AED 1,059.7 million, reflecting a 6.8% growth in reported currency from continuing operations compared to last year, and a 7.4% increase on a constant currency basis.

Profitability continued its steady growth trajectory, with the Company's reported profit of AED 175.3 million (of which AED 118.7 million is a one off capital gain), representing a significant improvement compared to AED 35.0 million in the previous year (of which AED 37.6 million was a one off capital gain),. EBITDA from continuing operations also grew by 15% versus last year, reaching AED 101.9 million, demonstrating the successful execution of strategic initiatives and ongoing operational efficiency projects.

These results highlight our continued progress in maintaining a strong balance between investments, a solid capital structure, and sustainable long-term shareholder value creation. Our strong market position continues to be reinforced by the dedication and commitment of our teams across all operating regions.

The name of the chairman of the company or the authorized signatory	**Sheikh Saqer Bin Humaid Al Qassimi**
Signature and Date	**12/02/2026**
Company's Seal	

Julphar
POBox 997 Ras Al Khaimah
United Arab Emirates

جلفار
صندوق بريد 997 رأس الخيمة
الإمارات العربية المتحدة

T +971 7 246 1461
F +971 7 246 2462
E info@julphar.net

الخليج للصناعات الدوائية
Gulf Pharmaceutical Industries